Research interests
EDG-7500 study funded by Edgewise Therapeutics, Inc.[2]
2025 to 2027
Presented “Outpatient CV Care: Prioritizing During a Pandemic” on June 22, 2020
As of 2020 · Last known relationship
Deepa C Upadhyaya is a Duke University cardiologist whose clinical and research work centers on hypertrophic cardiomyopathy and cardiovascular imaging. She is an Assistant Professor of Medicine in Cardiology and is described as an HCM cardiologist with echocardiography and cardiac imaging expertise. Her current research portfolio includes studies of sotagliflozin, EDG-7500, mavacamten, and MAPLE-HCM, with listed activity spanning 2023 to 2027. Upadhyaya completed an M.D. at Northeastern Ohio Medical University in 2004, an internal medicine internship at Baystate Medical Center, residency at Case Western Reserve University, and cardiology fellowships at Cleveland Clinic Florida and the University of California, San Francisco. In 2020, she served as Director of Quality for CV Disease and the Virtual Visit Task Force at Mid America Heart Institute-St. Luke Cardiology.
Each topic is linked to its supporting source in Sources.
Training includes Presented “Outpatient CV Care: Prioritizing During a Pandemic” on June 22, 2020, Cardiology fellowship at the University of California, San Francisco, Cardiology fellowship at Cleveland Clinic Florida, and Internal medicine residency at Case Western Reserve University, plus 4 more records.
Explore education and trainingAs of 2020
As of 2010
As of 2009
As of 2007
As of 2005
As of 2004
EDG-7500 study funded by Edgewise Therapeutics, Inc.[2]
2025 to 2027
MAPLE-HCM study funded by Cytokinetics, Inc.[2]
2023 to 2026
Mavacamten and symptomatic nonobstructive hypertrophic cardiomyopathy study funded by MyoKardia, Inc.[2]
2023 to 2026
SONATA-HCM study funded by Lexicon Pharmaceuticals[2]
2025 to 2027